• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Assessment of growth hormone (GH) plasma clearance rate, half-life, and volume of distribution in acromegalic patients: the combined GH-octreotide infusion.

作者信息

Lanzi R, Andreotti A C, Caumo A, Manzoni M F, Losa M, Malighetti M E, Pontiroli A E

机构信息

Istituto Scientifico San Raffaele, Cattedra di Clinica Medica, Milan, Italy.

出版信息

J Clin Endocrinol Metab. 1995 Nov;80(11):3279-83. doi: 10.1210/jcem.80.11.7593438.

DOI:10.1210/jcem.80.11.7593438
PMID:7593438
Abstract

In acromegaly, high GH levels are primarily attributable to GH hypersecretion, but the contribution of GH clearance is still under debate and is difficult to assess. In the present study, GH plasma clearance rate (PCR), half-life (t1/2), and volume of distribution (VD) were assessed in seven acromegalic patients and seven normal lean subjects, after suppression of endogenous GH release by octreotide, with use of a constant GH infusion. An octreotide sc infusion was started the night before the day of the test (2100 h) and maintained throughout the study. On the day of the test, exogenous GH was constantly infused iv for 6 h (0900-1500 h) in order to achieve a new steady state of GH levels. After the cessation of GH infusion, the decay curve of serum GH levels was monitored for 1 h. In both groups, GH PCR was calculated from the steady state serum GH levels, and GH t1/2 was estimated from the monoexponential analysis of the GH disappearance curve. Estimates of VD were derived from PCR and t1/2. In acromegalic patients, GH PCR was 2.5 +/- 0.2 mL/kg.min-1, and GH t1/2 and VD were 15.7 +/- 1.0 min and 54.9 +/- 5.5 mL/kg, respectively. GH PCR and GH t1/2 of acromegalic patients were higher and lower, respectively, than those of normal subjects (PCR, 1.7 +/- 0.2 mL/kg.min-1, P < 0.02; t1/2, 18.4 +/- 0.6 min, P < 0.05). VD was not significantly different in the two groups. In summary, in acromegalic patients GH kinetic parameters can be reliably assessed by using a constant GH infusion after suppression of endogenous GH release by octreotide. Our results also indicate that the increased circulating GH levels observed in acromegaly are attributable only to GH overproduction and do not depend on an alteration in the processes of GH distribution or disappearance.

摘要

相似文献

1
Assessment of growth hormone (GH) plasma clearance rate, half-life, and volume of distribution in acromegalic patients: the combined GH-octreotide infusion.
J Clin Endocrinol Metab. 1995 Nov;80(11):3279-83. doi: 10.1210/jcem.80.11.7593438.
2
Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men.
J Clin Endocrinol Metab. 1999 Aug;84(8):2862-9. doi: 10.1210/jcem.84.8.5881.
3
A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly.肢端肥大症患者鼻内给药与注射用奥曲肽的随机对照研究。
J Clin Endocrinol Metab. 1992 Jul;75(1):163-9. doi: 10.1210/jcem.75.1.1619006.
4
Galanin decreases circulating growth hormone levels in acromegaly.
J Clin Endocrinol Metab. 1992 Jun;74(6):1296-300. doi: 10.1210/jcem.74.6.1375598.
5
Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.生长抑素类似物奥曲肽对难治性肢端肥大症患者的剂量反应研究及长期疗效
J Clin Endocrinol Metab. 1989 May;68(5):873-81. doi: 10.1210/jcem-68-5-873.
6
Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion.肢端肥大症患者和正常男性的脉冲式生长激素分泌:生长激素释放激素输注的影响
J Clin Endocrinol Metab. 1990 Sep;71(3):585-90. doi: 10.1210/jcem-71-3-585.
7
Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.新型多配体生长抑素类似物SOM230与奥曲肽在肢端肥大症患者中的药代动力学-药效学比较
Clin Pharmacol Ther. 2005 Jul;78(1):69-80. doi: 10.1016/j.clpt.2005.04.003.
8
Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly.肢端肥大症患者中生长激素(GH)和催乳素对重复给予生长激素释放激素的反应。
J Clin Endocrinol Metab. 1986 Aug;63(2):475-80. doi: 10.1210/jcem-63-2-475.
9
Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.奥曲肽可抑制因异位生长激素释放激素(GHRH)分泌所致肢端肥大症患者体内的生长激素(GH)和生长激素释放激素(GHRH)。
J Clin Endocrinol Metab. 1989 Feb;68(2):499-504. doi: 10.1210/jcem-68-2-499.
10
Growth hormone-releasing hormone infusion in patients with active acromegaly.
J Clin Endocrinol Metab. 1986 Jul;63(1):88-93. doi: 10.1210/jcem-63-1-88.

引用本文的文献

1
Model informed quantification of the feed-forward stimulation of growth hormone by growth hormone-releasing hormone.模型指导下的促生长激素释放激素对生长激素的前馈刺激的定量分析。
Br J Clin Pharmacol. 2020 Aug;86(8):1575-1584. doi: 10.1111/bcp.14265. Epub 2020 Mar 9.
2
Regulation of Vascular Calcification by Growth Hormone-Releasing Hormone and Its Agonists.生长激素释放激素及其激动剂对血管钙化的调节作用。
Circ Res. 2018 May 11;122(10):1395-1408. doi: 10.1161/CIRCRESAHA.117.312418. Epub 2018 Apr 4.
3
A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds.
两步去卷积分析信息的群体药效动力学建模方法用于靶向内源性脉冲化合物的药物。
J Pharmacokinet Pharmacodyn. 2017 Aug;44(4):389-400. doi: 10.1007/s10928-017-9526-0. Epub 2017 May 11.